NCT05793333 Predictors of Node Positivity in Endometrial Cancer
| NCT ID | NCT05793333 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Condition | Endometrial Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-01-10 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-01-10 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the role of histological and moleculr profile of endometrial cancer patietns in predicting the risk of nodal metastases in endometrila cancer patients.
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Histologically confirmed endometrila cancer * Data on molecular genomic profiling (POLE mutated, p53 abnormalities, MMRd/MSI-H, and NSMP) * Data on histological characteristics of the ttumor * Execution of sentinel node mapping * Data on sentinel node status (negative vs. positive) Exclusion Criteria: * Stage IVB endoemtrial cancer * consent withdraw
Contact & Investigator
Giorgio Bogani, MD
STUDY CHAIR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Frequently Asked Questions
Who can join the NCT05793333 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05793333 currently recruiting?
Yes, NCT05793333 is actively recruiting participants. Contact the research team at grazia.casadei@istitutotumori.mi.it for enrollment information.
Where is the NCT05793333 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT05793333 clinical trial?
NCT05793333 is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The principal investigator is Giorgio Bogani, MD at Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.